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Introduction: Chronic obstructive pulmonary disease (COPD) patients with mucus hyperse-
cretion tend to demonstrate increased frequency of infective exacerbations and a steeper slope 
of decline in lung function. Enhanced mucociliary clearance with high-frequency chest wall 
oscillation (HFCWO) devices previously used in cystic fibrosis and bronchiectasis patients 
may offer the opportunity for community-based, self-managed therapy to improve quality of 
life and lung function.
Study design and methods: A randomized controlled crossover pilot study of HFCWO com-
pared with conventional treatment was conducted in 22 patients with moderate to severe COPD 
and mucus hypersecretion. Patients spent 4 weeks using an HFCWO (SmartVest®) device and 
4 weeks in a conventional phase with a 2-week washout. Eleven patients started with HFCWO 
and changed to conventional treatment, whereas the other eleven patients started conventional 
treatment and crossed over to HFCWO.
Results: The patients were elderly with a mean age of 71 (standard deviation [SD] 10) years 
and were at the upper end of the normal range of body mass index (25 [SD 4.2] kg/m2). The 
majority of patients had moderate to severe COPD with a mean percentage predicted forced 
expiratory volume in 1 second of 41 (SD 15.6) and percentage predicted forced vital capacity 
of 73 (SD 17.7). Baseline sputum production was negatively correlated to lung function and 
positively to St George’s Respiratory Questionnaire. Symptom scores and St George’s Respiratory 
Questionnaire symptom dimension improved significantly (−8, P , 0.05). Sputum production 
showed a declining trend in the HFCWO phase, although not reaching statistical significance. 
The HFCWO device was well tolerated with good reported compliance.
Conclusion: This pilot study demonstrated that patients with advanced COPD and mucus 
hypersecretion at increased risk of declining lung function tolerated the HFCWO treatment 
well, leading to improvement in quality of life and reduced symptoms.
Keywords: sputum volume, bronchiectasis, symptom scopes
Background
Cough, sputum, and shortness of breath are cardinal features of chronic obstructive 
pulmonary disease (COPD). The natural history of COPD is characterized by a pro-
gressive reduction in exercise tolerance and health-related quality of life (HRQoL).1,2 
The rate of decline in lung function, which is a strong predictor of morbidity and 
mortality in COPD,3 as well as health care utilization,4 is higher in patients with mucus 
hypersecretion and recurrent exacerbations.5–7International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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There is currently a variety of methods to improve 
mucociliary clearance (MCC) that have been shown to be 
effective in chronic lung conditions associated with excess 
mucus production, such as cystic fibrosis (CF) and non-CF 
bronchiectasis. These include physical therapy techniques 
such as autogenic drainage, the active cycle of breathing 
technique,8 and adjuvant mechanical devices such as the 
flutter device9 and positive end-expiratory pressure.
High-frequency chest wall oscillation (HFCWO) is a 
technique utilizing automated pneumatic chest wall percus-
sion delivered through a vest and transmitted to the airways 
that allows patients to manage their condition independently 
in their own homes, thus reducing health care costs. HFCWO 
delivers pressurized air pulses to the external chest wall via 
the vest, which results in transient cephalad bias airflow 
spikes in the airways to loosen bronchial mucus so that 
the patient can more easily expel secretions by coughing. 
Although HFCWO is well tolerated in children with CF10–12 
and has shown demonstrable improvement in MCC,13 as well 
as in some institutionally managed adults with amyotrophic 
lateral sclerosis, there is currently very little evidence of 
usage or benefit in adults with COPD.14 The in vivo benefit 
of HFCWO in improving MCC is based on the hypothesis 
that cyclical mechanical stress on the airway mucosa may 
improve hydration of the airway surface layer by activation 
of the P2Y2 receptors.15 Intuitively, improved MCC may 
reduce airflow obstruction,16,17 subsequent exacerbations,18,19 
and rate of lung function decline, leading to improvement 
in HRQoL.20
This pilot study aimed to explore the impact of improved 
MCC by application of HFCWO on symptoms and HRQoL in 
patients with advanced COPD and mucus hypersecretion.
Study design and methods
Ethical approval was obtained from the local research and 
ethics committee. A randomized crossover study design was 
used to compare HFCWO with conventional   treatment. All 
COPD patients admitted to hospital or attending the emergency 
room in the preceding 12 months due to an exacerbation of 
their disease were invited to participate in the study. These 
patients were identified from the authors’ COPD database. 
Patients who gave written consent attended for a screening 
visit. The minimum inclusion criteria were: forced expiratory 
volume in 1 second (FEV1) , 0.8 predicted, ratio of FEV1 by 
forced vital capacity (FVC) (FEV1/FVC) , 0.7, and a daily wet 
sputum volume of 25 mL in the stable state for 3 consecutive 
days. Exclusion criteria included history of osteoporosis, 
significant gastro-oesophageal reflux, hiatus hernia, recent 
acute cardiac event (6 weeks), congestive cardiac failure, any 
significant musculoskeletal disorders, bronchiectasis, and 
asthma (excluded by   reversibility testing).
Patients were randomized to receive either HFCWO or 
conventional treatment in phase 1 for 4 weeks, followed by 
a 2-week “washout” phase. Subjects then crossed over to the 
alternative phase for the final 4 weeks. Assessments were 
carried out at the beginning and end of each phase.
The SmartVest® Airway Clearance System (Electromed, 
Inc, New Prague, MN) was used to deliver the HFCWO 
treatment for all patients in the HFCWO treatment group. 
The SmartVest system consists of an inflatable vest, which 
is worn over the torso, and an air pulse generator that pro-
duces and delivers the oscillating air pulses to the vest via 
a connecting air hose. The HFCWO group received two 
treatment sessions per day of 20 minutes each (morning and 
evening). The SmartVest air pulse generator was set at an 
optimum oscillating frequency of 13–15 Hz, based on indi-
vidual patient tolerance during the “tuning procedure,” and 
a pressure setting to achieve a tight but comfortably snug fit. 
Patients in the conventional treatment group followed their 
own COPD management regimen including all prescription 
medications, advice on the benefits of regular exercise, and 
cough clearance of sputum. Medication included a minimum 
of combination long-acting bronchodilator and inhaled corti-
costeroid as well as an acting anticholinergic inhaler.
Primary outcome measures included HRQoL, patient 
tolerability, and compliance of the SmartVest HFCWO 
device. Secondary outcome measures were spirometry and 
wet sputum volume. HRQoL was measured with the St 
George’s Respiratory Questionnaire (SGRQ)21 as well as 
with a nonstandardized symptom score measurement, which 
required subjects to rate five cardinal respiratory symptoms 
(cough, sputum, wheeze, shortness of breath, and exercise 
tolerance) as mild = 1, moderate = 2, or severe = 3.
A paired sample t-test was used to compare the results 
between the HFCWO and conventional phase. Baseline 
correlations were obtained using multiple linear regression 
analysis. An intention-to-treat analysis model was used for 
patients who dropped out during each phase of the study. 
Correction for type 1 errors for multiple statistical tests was 
not used.
Results
Thirty subjects (eight female) consented to participate in the 
pilot study. Twenty-two patients completed the trial. Eight 
patients developed exacerbations of COPD within the trial 
period and were consequently withdrawn from the trial. International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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The patients were elderly with a mean age of 71 (standard 
  deviation [SD] 10) years and were at the upper end of the 
normal range of body mass index (25 [SD 4.2] kg/m2).
The majority of patients had moderate to severe COPD 
with a mean FEV1% predicted of 41 (SD 15.6) and percent-
age predicted forced vital capacity (FVC%) of 73 (SD 17.7). 
The baseline daily wet sputum volume was variable with a 
mean volume of 39 (SD 23) mL/day, based on a 72-hour 
collection. Daily sputum expectoration at baseline correlated 
with a lower FEV1% predicted, as shown in Figure 1 (linear 
regression adjusted r2 = −0.114, P , 0.05).
SGRQ scores at baseline were symptom score 72 (SD 18), 
activity score 77 (SD17), impact of disease score 51 (SD23), 
and total score 63 (SD19). Three of the SGRQ dimension 
scores showed a significant predictive relationship when 
modeled with FEV1% predicted using a linear regression 
model: symptoms (coefficient β = −0.5, P , 0.016), activity 
(β = −0.7, P = 0.007), and total score (β = −0.4, P , 0.05). 
The SGRQ impact score remained nonsignificant.
There was no significant change in spirometry values 
(FEV1 or FVC) with HFCWO baseline FEV1 1.05 (SD 0.37) 
versus postintervention FEV1 1.07 (SD 0.38) L or in the 
conventional phase (baseline FEV1 0.97 [SD 0.37]) versus 
postintervention (FEV1 1.01 [SD 0.36] L, P = not significant), 
as shown in Figure 2.
Sputum expectoration remained individually variable 
but showed a trend toward a reduction after HFCWO. In 
the HFCWO phase, the mean change in sputum volume 
was −2.6 mL (range −53 to +27 mL), and in the conventional 
phase the mean change was +6 mL (range −70 to +40 mL), 
P = 0.06.
The baseline sputum volume significantly predicted the 
change in sputum volume with HFCWO, in a model includ-
ing age, sex, FEV1% predicted, FVC%, and body mass index 
(linear regression model coefficient β = 0.7, P = 0.024), 
whereas in the conventional phase, none of the variables was 
found to be significant.
There was a significant improvement in the mean total 
score in the five-symptom self-reported questionnaire in 
patients on HFCWO, P = 0.03. SGRQ scores showed a 
significant improvement in the symptom dimension (∂ = −8, 
P = 0.028), whereas impact of disease, activity, and total 
scores did not achieve a significant reduction (Table 1). There 
was no significant change in SGRQ scores in the conventional 
phase (Figure 3).
Discussion
Although the effect of HFCWO has been demonstrated to 
enhance MCC in children with CF,22 as well as in adults 
with bronchiectasis and neuromuscular disease,23 its use 
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Figure 1 scatter plot demonstrating the relationship between sputum volume (mL) and lung function (forced expiratory volume in 1 second percentage predicted [FeV1PreD]).International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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in COPD24 is novel. In this pilot study, the authors set out 
to explore the suitability of using this modality to improve 
MCC in patients at the moderate to severe end of the COPD 
spectrum, where increased sputum production and retention 
can lead to increased exacerbations, hospital admissions, 
and a more rapid decline in lung function.25 In addition to 
assessing the impact on HRQoL and sputum, another aim 
was to assess the tolerability and acceptability of this form of 
treatment in elderly patients with disabling COPD symptoms 
and often multiple comorbidities.
Toward this aim, it was found that patients demonstrated 
a significant improvement in HRQoL dimensions of SGRQ 
symptom control. The efficient daily clearance of sputum may 
have led to a decreased daily sputum volume at the end of 
the HFCWO phase. The HFCWO modality delivered by the 
SmartVest system was well tolerated in patients who often 
had significant disability including shortness of breath at rest. 
No subjects dropped out due to intolerance of the device.
The crossover study design was chosen to reduce the 
intersubject variability in physiological parameters, as each 
subject would act as their own matched control. It was decided 
to have two cohorts of patients, reversing the sequence of 
HFCWO/conventional versus conventional/HFCWO, to 
detect any residual effect on MCC after discontinuing the 
HFCWO treatment phase during the 2-week washout phase 
and none was detected. Placebo intervention for this study 
was deliberately not chosen, as the authors wished to com-
pare HFCWO with “usual treatment,” as is   currently usual 
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Figure 2 Boxplots representing median and interquartile range change in lung function (predicted forced expiratory volume in 1 second [FeV1] percent predicted and forced 
vital capacity [FVC] percent predicted) from baseline after intervention in high-frequency chest wall oscillation (phase 1) and conventional arm (phase 2).
Table 1 symptom and st george’s respiratory Questionnaire (sgrQ)21 dimension scores before and after intervention in each arm 
of the study
HFCWO before HFCWO after P Conventional before Conventional after P
symptom score 9.09 (3.3) 7.0 (4.7) 0.02 9.33 (2.3) 9.55 (2.0) ns
sgrQ symptom score 72 (18) 64 (16) 0.02 70 (18) 68 (17) ns
sgrQ activity score 77 (17) 78 (16) ns 80 (14) 75 (19) ns
sgrQ impact score 51 (23) 50 (19) ns 49 (19) 53 (19) ns
sgrQ total score 63 (19) 60 (17) ns 62 (15) 62 (17) ns
Note: Values in brackets indicate the standard deviation.
Abbreviations: FCWO, high-frequency chest wall oscillation; NS, not significant.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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  practice in a real-life setting. It was the authors’ hypothesis 
that patients with severe disabling symptoms from COPD 
were likely to accept and comply with a treatment that 
involved setting up and using a vibrating vest around their 
chest for 20 minutes twice a day only if they experienced 
a detectable benefit. This has been demonstrated in several 
trials where compliance levels have been found to be below 
50%.26,27 However, it is theoretically possible that a propor-
tion of the benefit demonstrated in HRQoL may indeed be 
due to a placebo “device” effect.
Although this pilot study was not statistically powered, a 
clinically significant improvement was found in the SGRQ 
symptom score as well as the SGRQ total score. The SGRQ 
dimension scores are considered to demonstrate a clinically 
relevant change if there is a mean reduction in the score of 
four or more units.28 However, when the five-point clini-
cal symptoms score was examined, there was a significant 
improvement in the HFCWO phase when compared with the 
conventional phase, which showed no change, although this 
symptom score was not standardized. When such disease-
specific quality of life (QoL) outcomes are compared with 
generic QoL measures, the scores were found to demonstrate 
similar changes. Although in the conventional phase the 
five-point symptom scores were marginally worse, both of 
these outcomes improved in the HFCWO arm. Hence, it is 
likely that the size of improvement detected in the HFCWO 
phase is due to the intervention, rather than being entirely 
a placebo effect.
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Analysis revealed a negative correlation between FEV1 
and sputum production and a positive correlation between 
FEV1 and HRQoL. Not only did a low FEV1 relate to a low 
HRQoL but also to increased sputum production. This would 
add credence to the current consensus that increased sputum 
production (and retention) may lead to an increased frequency 
of exacerbations and, in turn, to an increased rate of decline 
in FEV1.
29 As FEV1 decline is still the most reliable parameter 
of survival, this is a very powerful determinant of outcome 
in COPD patients.
A 25 mL/day mucus production threshold was chosen 
as a criterion for entry into the study after a comprehen-
sive search of the relevant literature. Drawing on previous 
experience from trials in CF and non-CF bronchiectatics, 
the authors were keen to exclude these patients from this 
trial, intending primarily to focus on the phenotype of 
COPD30 with airway obstruction and mucus hypersecretion 
as a novel area of use. The authors’ hypothesis of improved 
MCC leading to a reduction in exacerbation of COPD and 
rate of decline of FEV1 would be valid only in patients who 
exhibited both frequent exacerbations and increased mucus 
production. Patients who had at least one exacerbation in 
the last 12 months requiring a visit to hospital were invited 
to take part in this study. The subset of patients who were 
predominantly suffering from chronic bronchitis rather than 
having predominantly emphysema, where improved MCC 
may not be a relevant outcome, were especially sought for 
inclusion in the study. Clinical experience demonstrated that 
mucus production in generic COPD patients varied around 
10 ± 10 mL/day. Hence, the minimum mucus volume was set 
at a consensus level of 25 mL/day. High-resolution computed 
tomography scans were not routinely undertaken in these 
patients to exclude mild bronchiectasis. It is recognized that a 
proportion of COPD patients with excess sputum production 
may have undetected areas of bronchiectasis in their lungs. 
However, clinical criteria of persistent sputum purulence (in 
the absence of a clinically detectable exacerbation) and chest 
radiographic examination were used to avoid patients with 
obvious bronchiectasis.
Mucus production was widely variable in the study 
subjects, reflecting the range of FEV1 in this group. There 
was a consistent trend of reduction in mucus production in 
the HFCWO phase, when compared with the conventional 
phase, where the levels of sputum production remained 
stable or even increased. The baseline mucus production 
was the primary determinant in predicting the post-treatment 
mucus production during HFCWO treatment. Overall, there 
was a trend of reduction in sputum production by the end 
of the 4-week intervention period. This is likely to be due 
to efficient daily clearance, as well as a possible reduction in 
actual sputum production. Patterson et al explored sputum 
volumes in patients with bronchiectasis and also found 
significant variability, making this an unreliable measure 
of effectiveness of MCC modalities.31
In a Canadian study, with 15 severe COPD patients 
given a flutter device to improve MCC, the authors found an 
improvement in 2-hour postbronchodilator spirometry and 
exercise tolerance after 1 week of use.9 Therefore, it is likely 
that effective MCC in COPD patients may have an impact on 
the rate of decline in lung function in the future, although this 
was not demonstrated significantly in this pilot study.
Conclusion
This study was designed to explore the feasibility of using 
the HFCWO modality of mucus clearance in patients with 
advanced COPD. It was found that that the SmartVest 
HFCWO device was well tolerated and that subjects dem-
onstrated an improvement in symptom scores and QoL. 
A significant effect on lung function was not demonstrated, 
and the wet mucus quantities remained individually variable 
between patients. It is therefore feasible that HFCWO may 
have a role in enhancing mucus clearance in COPD patients 
with the “mucus hypersecretory” phenotype, and future 
studies may be able to explore the impact of MCC in lung 
function decline and prevention of exacerbations.
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